

A RodrÃ-guez-Lescure

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5661413/publications.pdf>

Version: 2024-02-01

86
papers

3,993
citations

249298

26
h-index

134545

62
g-index

89
all docs

89
docs citations

89
times ranked

5240
citing authors

#	ARTICLE	IF	CITATIONS
1	Multidisciplinary consensus on the criteria for fertility preservation in cancer patients. Clinical and Translational Oncology, 2022, 24, 227-243.	1.2	17
2	Bone loss induced by cancer treatments in breast and prostate cancer patients. Clinical and Translational Oncology, 2022, 24, 2090-2106.	1.2	9
3	Multidisciplinary consensus on cancer management during pregnancy. Clinical and Translational Oncology, 2021, 23, 1054-1066.	1.2	14
4	SEOM clinical guidelines 2020. Clinical and Translational Oncology, 2021, 23, 911-912.	1.2	0
5	Liquid biopsy in oncology: a consensus statement of the Spanish Society of Pathology and the Spanish Society of Medical Oncology. Clinical and Translational Oncology, 2020, 22, 823-834.	1.2	29
6	TESEO, cancer-associated thrombosis registry from the Spanish Society of Medical Oncology (SEOM). Clinical and Translational Oncology, 2020, 22, 1423-1424.	1.2	0
7	Study of the Spanish Society of Medical Oncology (SEOM) on the access to oncology drugs and predictive biomarkers in Spain. Clinical and Translational Oncology, 2020, 22, 2253-2263.	1.2	9
8	2019 SEOM guidelines (the end of a decade). Clinical and Translational Oncology, 2020, 22, 169-170.	1.2	1
9	Re-interpretation of PAM50 gene expression as quantitative tumor dimensions shows utility for clinical trials: application to prognosis and response to paclitaxel in breast cancer. Breast Cancer Research and Treatment, 2019, 175, 129-139.	1.1	14
10	Phase III evaluating the addition of fulvestrant (F) to anastrozole (A) as adjuvant therapy in postmenopausal women with hormone receptor-positive HER2-negative (HR+/HER2 ⁻) early breast cancer (EBC): results from the GEICAM/2006 ^â 10 study. Breast Cancer Research and Treatment, 2019, 177, 115-125.	1.1	20
11	A Pathology-Based Combined Model to Identify PAM50 Non-luminal Intrinsic Disease in Hormone Receptor-Positive HER2-Negative Breast Cancer. Frontiers in Oncology, 2019, 9, 303.	1.3	8
12	Prediction of chemotherapy benefit by EndoPredict in patients with breast cancer who received adjuvant endocrine therapy plus chemotherapy or endocrine therapy alone. Breast Cancer Research and Treatment, 2019, 176, 377-386.	1.1	61
13	Abstract GS2-04: Efficacy results from CIBOMA/2004-01_GEICAM/2003-11 study: A randomized phase III trial assessing adjuvant capecitabine after standard chemotherapy for patients with early triple negative breast cancer. , 2019, , .		7
14	First results of a prospective registry in unresectable locally advanced or metastatic breast cancer patients: GEICAM/2014-03 (RegistEM).. Journal of Clinical Oncology, 2019, 37, 1077-1077.	0.8	1
15	Abstract P2-13-04: Impact of the adjuvant treatment with trastuzumab in HER2 positive breast cancer in the real-world setting. Analysis of two cohorts (1997-2005/2006-2015) in 1970 patients. , 2019, , .		0
16	Abstract P2-08-04: Prediction of distant recurrence by EndoPredict in patients with estrogen receptor-positive, HER2-negative breast cancer who received adjuvant endocrine therapy plus chemotherapy (ET+C) or endocrine therapy alone (ET). , 2019, , .		0
17	NOLUS: a predictive model to identify Basal-like and HER2-enriched intrinsic subtypes based on estrogen receptor (ER), progesterone receptor (PR) and Ki67 immunohistochemistry (IHC) in hormone receptor-positive/HER2-negative (HR+/HER2 ⁻) breast cancer (BC). European Journal of Cancer, 2018, 92, S138.	1.3	0
18	PDGFR and IGF-1R Inhibitors Induce a G2/M Arrest and Subsequent Cell Death in Human Glioblastoma Cell Lines. Cells, 2018, 7, 131.	1.8	17

#	ARTICLE	IF	CITATIONS
19	Prognostic role for the derived neutrophil-to-lymphocyte ratio in early breast cancer: a GEICAM/9906 substudy. <i>Clinical and Translational Oncology</i> , 2018, 20, 1548-1556.	1.2	10
20	Advanced breast cancer clinical nursing curriculum: review and recommendations. <i>Clinical and Translational Oncology</i> , 2017, 19, 251-260.	1.2	16
21	Phase III evaluating the addition of fulvestrant (F) to anastrozol (A) as adjuvant therapy in postmenopausal women with hormone receptor positive HER2 negative (HR+/HER2-) early breast cancer (EBC): Results from the GEICAM/2006-10 study. <i>Annals of Oncology</i> , 2017, 28, v43.	0.6	4
22	Lack of cytomegalovirus detection in human glioma. <i>Virology Journal</i> , 2017, 14, 216.	1.4	24
23	Gestational breast cancer: distinctive molecular and clinico-epidemiological features. GEICAM/2012-03 study. <i>Annals of Oncology</i> , 2016, 27, vi46.	0.6	0
24	Prognostic ability of EndoPredict compared to research-based versions of the PAM50 risk of recurrence (ROR) scores in node-positive, estrogen receptor-positive, and HER2-negative breast cancer. A GEICAM/9906 sub-study. <i>Breast Cancer Research and Treatment</i> , 2016, 156, 81-89.	1.1	38
25	Nab-Paclitaxel in Metastatic Breast Cancer: Defining the Best Patient Profile. <i>Current Cancer Drug Targets</i> , 2016, 16, 415-428.	0.8	10
26	Outcomes of single versus double hormone receptor positive breast cancer.. <i>Journal of Clinical Oncology</i> , 2016, 34, 569-569.	0.8	1
27	Defining Breast Cancer Intrinsic Subtypes by Quantitative Receptor Expression. <i>Oncologist</i> , 2015, 20, 474-482.	1.9	145
28	Epirubicin Plus Cyclophosphamide Followed by Docetaxel Versus Epirubicin Plus Docetaxel Followed by Capecitabine As Adjuvant Therapy for Node-Positive Early Breast Cancer: Results From the GEICAM/2003-10 Study. <i>Journal of Clinical Oncology</i> , 2015, 33, 3788-3795.	0.8	56
29	Abstract P5-19-21: TRASTYVERE study: A retrospective analysis of HER2-positive metastatic breast cancer (MBC) patients treated in Spain with lapatinib (L) plus trastuzumab (T).. , 2015, . .		0
30	Clinical validation of the EndoPredict test in node-positive, chemotherapy-treated ER+/HER2 ⁺ breast cancer patients: results from the GEICAM 9906 trial. <i>Breast Cancer Research</i> , 2014, 16, R38.	2.2	133
31	Predicting response and survival in chemotherapy-treated triple-negative breast cancer. <i>British Journal of Cancer</i> , 2014, 111, 1532-1541.	2.9	100
32	Subtype analysis from the GEICAM/2003-02 study: High-risk, node-negative breast cancer patients treated with adjuvant fluorouracil, doxorubicin, and cyclophosphamide (FAC) versus FAC followed by weekly paclitaxel.. <i>Journal of Clinical Oncology</i> , 2014, 32, 11107-11107.	0.8	1
33	Preliminary results from TRASTYVERE study: A retrospective analysis of HER2-positive (HER2) metastatic breast cancer (MBC) patients treated in Spain with lapatinib (L) plus trastuzumab (T).. <i>Journal of Clinical Oncology</i> , 2014, 32, 614-614.	0.8	0
34	Adjuvant docetaxel, doxorubicin, and cyclophosphamide in node-positive breast cancer: 10-year follow-up of the phase 3 randomised BCIRG 001 trial. <i>Lancet Oncology</i> , The, 2013, 14, 72-80.	5.1	192
35	PAM50 proliferation score as a predictor of weekly paclitaxel benefit in breast cancer. <i>Breast Cancer Research and Treatment</i> , 2013, 138, 457-466.	1.1	96
36	Bevacizumab in advanced breast cancer. <i>Anti-Cancer Drugs</i> , 2013, 24, 975-979.	0.7	0

#	ARTICLE	IF	CITATIONS
37	Fluorouracil, Doxorubicin, and Cyclophosphamide (FAC) Versus FAC Followed by Weekly Paclitaxel As Adjuvant Therapy for High-Risk, Node-Negative Breast Cancer: Results From the GEICAM/2003-02 Study. <i>Journal of Clinical Oncology</i> , 2013, 31, 2593-2599.	0.8	52
38	Obesity and survival in operable breast cancer patients treated with adjuvant anthracyclines and taxanes according to pathological subtypes: a pooled analysis. <i>Breast Cancer Research</i> , 2013, 15, R105.	2.2	80
39	Abstract P2-11-06: Comparison of PAM50 risk of recurrence (ROR) scores with EndoPredict for predicting risk of distant metastasis in ER+/HER2-, early node-positive breast cancer patients treated with adjuvant chemotherapy - A GEICAM/ 9906 sub-study. , 2013, , .		2
40	The effect of guideline-consistent antiemetic therapy on chemotherapy-induced nausea and vomiting (CINV): the Pan European Emesis Registry (PEER). <i>Annals of Oncology</i> , 2012, 23, 1986-1992.	0.6	248
41	PAM50 Breast Cancer Subtyping by RT-qPCR and Concordance with Standard Clinical Molecular Markers. <i>BMC Medical Genomics</i> , 2012, 5, 44.	0.7	250
42	Pilot study on workload estimate in breast cancer, lung cancer and colorectal cancer in a Medical Oncology Service at Valme hospital. <i>Clinical and Translational Oncology</i> , 2012, 14, 820-826.	1.2	1
43	Mamasteam: Bevacizumab (BVZ) in the Treatment of Breast Cancer in Advanced Lines of Treatment, a New Model for the Assessment of Activity in Advanced Cancer. <i>Annals of Oncology</i> , 2012, 23, ix140.	0.6	0
44	Phase II trial with letrozole to maximum response as primary systemic therapy in postmenopausal patients with ER/PgR[+] operable breast cancer. <i>Clinical and Translational Oncology</i> , 2012, 14, 125-131.	1.2	62
45	Functions and workload of medical oncologists in Spain. <i>Clinical and Translational Oncology</i> , 2012, 14, 423-429.	1.2	7
46	Abstract P2-10-11: Prognostic performance of the EndoPredict score in node-positive chemotherapy-treated ER+/HER2~ breast cancer patients: results from the GEICAM/9906 trial. , 2012, , .		3
47	Phase I/II study of biweekly vinorelbine and oxaliplatin as first-line treatment in patients with metastatic breast cancer. <i>Anti-Cancer Drugs</i> , 2011, 22, 283-289.	0.7	4
48	P323 Second interim analysis of dose density with zoledronic acid treatment in metastatic breast cancer patients. ZARAS study. <i>Breast</i> , 2011, 20, S78-S79.	0.9	1
49	Regional and seasonal influence in patient's toxicity to adjuvant chemotherapy for early breast cancer. <i>Breast Cancer Research and Treatment</i> , 2011, 125, 273-278.	1.1	5
50	An Overview of Letrozole in Postmenopausal Women with Hormone-Responsive Breast Cancer. <i>Advances in Therapy</i> , 2011, 28, 1045-1058.	1.3	21
51	Local versus central laboratory discrepancies in the determination of triple-negative breast cancer (TNBC) status in a large phase III (CIBOMA/2004-01/GEICAM/2003~11) trial assessing adjuvant capecitabine (C) maintenance therapy after standard chemotherapy (CT) in early breast cancer (EBC) patients (pts).. <i>Journal of Clinical Oncology</i> . 2011, 29, 1022-1022.	0.8	1
52	Determining agreement between immunohistochemistry and RT-qPCR for standard biomarkers in breast cancer: Validation on GEICAM 9906 clinical trial.. <i>Journal of Clinical Oncology</i> , 2011, 29, 611-611.	0.8	1
53	Final analysis of dose density with zoledronic acid treatment in metastatic breast cancer patients: ZARAS study.. <i>Journal of Clinical Oncology</i> , 2011, 29, 630-630.	0.8	0
54	P1-06-04: PAM50 Proliferation Index Predicts Response to Weekly Adjuvant Paclitaxel in Node-Positive Operable Breast Cancer.. , 2011, , .		2

#	ARTICLE	IF	CITATIONS
55	Circulating tumour cell analysis as an early marker for relapse in stage II and III colorectal cancer patients: a pilot study. <i>Clinical and Translational Oncology</i> , 2010, 12, 142-147.	1.2	23
56	Molecular predictors of efficacy of adjuvant weekly paclitaxel in early breast cancer. <i>Breast Cancer Research and Treatment</i> , 2010, 123, 149-157.	1.1	77
57	Maintenance treatment with Pegylated liposomal doxorubicin versus observation following induction chemotherapy for metastatic breast cancer: GEICAM 2001-01 study. <i>Breast Cancer Research and Treatment</i> , 2010, 122, 169-176.	1.1	69
58	Adjuvant chemotherapy in young women with breast cancer. <i>Breast Cancer Research and Treatment</i> , 2010, 123, 39-41.	1.1	121
59	Adjuvant Docetaxel for High-Risk, Node-Negative Breast Cancer. <i>New England Journal of Medicine</i> , 2010, 363, 2200-2210.	13.9	169
60	O145 First safety data from a randomised phase III trial comparing adjuvant epirubicin+cyclophosphamide + docetaxel (EC + T) vs ET + capecitabine (X) in N+ operable breast cancer (BC). <i>Breast</i> , 2009, 18, S55.	0.9	1
61	Cost-effectiveness analysis of docetaxel (Taxotere®) vs. 5-fluorouracil in combined therapy in the initial phases of breast cancer. <i>Clinical and Translational Oncology</i> , 2009, 11, 41-47.	1.2	12
62	Diagnosis and medical treatment of breast cancer. Cordoba Consensus of 2007. <i>Clinical and Translational Oncology</i> , 2008, 10, 552-559.	1.2	1
63	Randomized Phase 3 Trial of Fluorouracil, Epirubicin, and Cyclophosphamide Alone or Followed by Paclitaxel for Early Breast Cancer. <i>Journal of the National Cancer Institute</i> , 2008, 100, 805-814.	3.0	208
64	Multicenter, randomized phase III study of adjuvant chemotherapy for high-risk, node-negative breast cancer comparing tac with fac: 5-year efficacy analysis of the GEICAM 9805 trial. <i>Journal of Clinical Oncology</i> , 2008, 26, 542-542.	0.8	15
65	Phase I-II study of IV vinorelbine (NVB) and oxaliplatin (OXP) every two weeks (q2w) in metastatic breast cancer (MBC): Interim results of the phase II trial. <i>Journal of Clinical Oncology</i> , 2008, 26, 1104-1104.	0.8	0
66	Evidence-based use of taxanes in the adjuvant setting of breast cancer. A review of randomized phase III trials. <i>Cancer Treatment Reviews</i> , 2007, 33, 474-483.	3.4	16
67	The Use of Taxanes in the Neoadjuvant Treatment of Breast Cancer: A Review of Randomized Phase II/III Trials. <i>Clinical Breast Cancer</i> , 2007, 7, 764-774.	1.1	4
68	P128 Phase II trial with letrozole (2.8 mg) to maximal response as neoadjuvant endocrine therapy in postmenopausal patients with ER/PgR[+] operable breast cancer. <i>Breast</i> , 2007, 16, S49-S50.	0.9	2
69	Subgroup analysis of GEICAM 9906 trial comparing six cycles of FE90C (FEC) to four cycles of FE90C followed by 8 weekly paclitaxel administrations (FECp): Relevance of HER2 and hormonal status (HR). <i>Journal of Clinical Oncology</i> , 2007, 25, 10598-10598.	0.8	6
70	Toxicity and health-related quality of life in breast cancer patients receiving adjuvant docetaxel, doxorubicin, cyclophosphamide (TAC) or 5-fluorouracil, doxorubicin and cyclophosphamide (FAC): impact of adding primary prophylactic granulocyte-colony stimulating factor to the TAC regimen. <i>Annals of Oncology</i> , 2006, 17, 1205-1212.	0.6	171
71	Adjuvant Docetaxel for Node-Positive Breast Cancer. <i>New England Journal of Medicine</i> , 2005, 352, 2302-2313.	13.9	892
72	Toxicity and health-related quality of life (HRQoL) in node-negative breast cancer (BC) patients (pts) receiving adjuvant treatment with TAC (docetaxel, doxorubicin, cyclophosphamide) or FAC (5-fluorouracil, doxorubicin, cyclophosphamide): Impact of adding prophylactic growth factors (GF) to TAC. GEICAM Study 9805. <i>Journal of Clinical Oncology</i> , 2005, 23, 604-604.	0.8	11

#	ARTICLE	IF	CITATIONS
73	Epirubicin cyclophosphamide adjuvant chemotherapy plus tamoxifen administered concurrently versus sequentially: randomized phase III trial in postmenopausal node-positive breast cancer patients. A GEICAM 9401 study. <i>Annals of Oncology</i> , 2004, 15, 79-87.	0.6	69
74	Prophylactic growth factor (GF) support with adjuvant docetaxel, doxorubicin, and cyclophosphamide (TAC) for node-negative breast cancer (BC): An interim safety analysis of the GEICAM 9805 study. <i>Journal of Clinical Oncology</i> , 2004, 22, 620-620.	0.8	16
75	Multicenter, randomized phase III study of adjuvant chemotherapy for axillary positive breast cancer (APBC) comparing 6 cycles (cy) of FEC vs 4 cy of FEC followed by 8 weekly paclitaxel (T) administrations: Safety analysis of GEICAM 9906 trial. <i>Journal of Clinical Oncology</i> , 2004, 22, 596-596.	0.8	7
76	Influence of cytochrome P450 CYP2C9 genotypes in lung cancer risk. <i>Cancer Letters</i> , 2002, 180, 41-46.	3.2	23
77	N-acetyltransferase 2 single-nucleotide polymorphisms and risk of gastric carcinoma. <i>European Journal of Clinical Pharmacology</i> , 2002, 58, 115-118.	0.8	17
78	Functionally Active Duplications of the <i>CYP2D6</i> Gene Are More Prevalent among Larynx and Lung Cancer Patients. <i>Oncology</i> , 2001, 61, 59-63.	0.9	38
79	Weekly continuous infusion of 5-fluorouracil with oral leucovorin in metastatic breast cancer patients with primary resistance to doxorubicin. <i>Breast Cancer Research and Treatment</i> , 1998, 50, 167-174.	1.1	3
80	Increased risk for hepatocellular carcinoma in NAT2-slow acetylators and CYP2D6-rapid metabolizers. <i>Pharmacogenetics and Genomics</i> , 1996, 6, 501-512.	5.7	59
81	Acute and anticipatory emesis in breast cancer patients. <i>Supportive Care in Cancer</i> , 1996, 4, 370-377.	1.0	16
82	RsaI Polymorphism at the CYP2E1 Locus and Risk of Primary Liver Cancer. <i>Clinical Pharmacology and Therapeutics</i> , 1996, 59, 134-134.	2.3	0
83	RsaI polymorphism at the cytochrome P4502E1 locus and risk of hepatocellular carcinoma. <i>Gut</i> , 1996, 39, 330-333.	6.1	48
84	CYP2D6 genes and risk of liver cancer. <i>Lancet</i> , The, 1995, 345, 830-831.	6.3	59
85	Clinical activity of chronic oral etoposide in previously treated metastatic breast cancer. <i>Journal of Clinical Oncology</i> , 1994, 12, 986-991.	0.8	55
86	Prednimustine-Induced Myoclonus—a Report of Three Cases. <i>Acta Oncológica</i> , 1994, 33, 81-82.	0.8	7